InterMune, Inc.
(Public, NASDAQ:ITMN) Watch this stockFind more results for
itmn
Advertisement
Events
Nov 5, 2009
Q3 2009 Earnings Conference Call -
Nov 5, 2009
Q3 2009 Earnings Release
Nov 4, 2009
Oppenheimer & Co. Healthcare Conference
Oct 5, 2009
JMP Securities Healthcare Focus Conference
|
More events from AOL Finance »
|
Key stats and ratios
| Q2 (Jun '09) | 2008 | |
| Net profit margin | -462.41% | -203.19% |
| Operating margin | -442.08% | -206.19% |
| EBITD margin | - | -194.05% |
| Return on average assets | -81.95% | -45.02% |
| Return on average equity | - | - |
| Employees | 118 | - |
Address
3280 Bayshore Boulevard
Brisbane, CA 94005
United States - Map
+1-415-4662200 (Phone)
+1-415-4662300 (Fax)
Brisbane, CA 94005
United States - Map
+1-415-4662200 (Phone)
+1-415-4662300 (Fax)
Website links
Company website:
http://www.intermune.com
http://www.intermune.com
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
InterMune, Inc. discussions
View all discussions »Description
InterMune, Inc. (InterMune) is a biotech company focused on developing and commercializing therapies in pulmonology and hepatology. As of December 31, 2008, the Company’s development programs included pirfenidone for idiopathic pulmonary fibrosis (IPF) and the hepatitis C virus (HCV) protease inhibitor program. In October 2006, the Company entered into an agreement with Hoffmann-LaRoche Inc. and F. Hoffmann-LaRoche Ltd. (Roche) to develop and commercialize products from its chronic HCV protease inhibitor program, including its lead candidate compound ITMN-191. Effective March 2007, the Company discontinued development of Actimmune for IPF.
Officers and directors
| Daniel G. Welch | Chairman of the Board, Chief Executive Officer, President | |
| John C. Hodgman | Chief Financial Officer, Senior Vice President - Finance | |
| Robin J. Steele Esq. | Senior Vice President - Legal Affairs, General Counsel, Corporate Secretary | |
| Howard A. Simon Esq. | Senior Vice President - Human Resources and Corporate Services, Associate General Counsel | |
| Williamson Z. Bradford M.D., Ph.D. | Senior Vice President - Clinical Science and Biometrics | |
| Steven B. Porter M.D., Ph.D. | Chief Medical Officer | |
| Marianne T. Armstrong Ph.D. | Chief Medical Affairs and Regulatory Officer | |
| Lars G. Ekman M.D., Ph.D. | Lead Independent Director | |
| James I. Healy M.D., Ph.D. | Director | |
| Jonathan S. Leff | Director |